C4 Therapeutics, Inc (CCCC)

$6.91

+0.04

(+0.58%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on C4 Therapeutics, Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 11.07M → 3.26M (in $), with an average decrease of 70.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -27.03M → -34.75M (in $), with an average decrease of 28.5% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 324.0%

Performance

  • $6.76
    $7.06
    $6.91
    downward going graph

    2.17%

    Downside

    Day's Volatility :4.25%

    Upside

    2.12%

    downward going graph
  • $1.06
    $11.88
    $6.91
    downward going graph

    84.66%

    Downside

    52 Weeks Volatility :91.08%

    Upside

    41.84%

    downward going graph

Returns

PeriodC4 Therapeutics, IncSector (Health Care)Index (Russel 2000)
3 Months
14.31%
-0.7%
0.0%
6 Months
265.43%
6.6%
0.0%
1 Year
116.04%
3.7%
-1.5%
3 Years
-78.25%
14.0%
-21.8%

Highlights

Market Capitalization
471.3M
Book Value
$4.07
Earnings Per Share (EPS)
-2.67
Wall Street Target Price
18.5
Profit Margin
0.0%
Operating Margin TTM
-1147.72%
Return On Assets TTM
-21.53%
Return On Equity TTM
-49.5%
Revenue TTM
20.8M
Revenue Per Share TTM
0.42
Quarterly Revenue Growth YOY
14.299999999999999%
Gross Profit TTM
-86.7M
EBITDA
-137.2M
Diluted Eps TTM
-2.67
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.85
EPS Estimate Next Year
-1.92
EPS Estimate Current Quarter
-0.68
EPS Estimate Next Quarter
-0.53

Analyst Recommendation

Buy
    70%Buy
    17%Hold
    11%Sell
Based on 17 Wall street analysts offering stock ratings for C4 Therapeutics, Inc(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
3
4
5
Sell
2
2
2

Analyst Forecast

What analysts predicted

Upside of 167.73%

Current $6.91
Target $18.50

Company Financials

FY18Y/Y Change
Revenue
19.4M
-
Net Income
-15.7M
-
Net Profit Margin
-81.14%
-
FY19Y/Y Change
Revenue
21.4M
↑ 10.42%
Net Income
-34.1M
↑ 117.04%
Net Profit Margin
-159.48%
↓ 78.34%
FY20Y/Y Change
Revenue
33.2M
↑ 55.25%
Net Income
-66.3M
↑ 94.54%
Net Profit Margin
-199.83%
↓ 40.35%
FY21Y/Y Change
Revenue
45.8M
↑ 37.93%
Net Income
-86.0M
↑ 29.7%
Net Profit Margin
-187.92%
↑ 11.91%
FY22Y/Y Change
Revenue
31.1M
↓ 32.08%
Net Income
-126.5M
↑ 47.03%
Net Profit Margin
-406.8%
↓ 218.88%
FY23Y/Y Change
Revenue
20.8M
↓ 33.25%
Net Income
-132.5M
↑ 4.74%
Net Profit Margin
-638.34%
↓ 231.54%
Q3 FY22Q/Q Change
Revenue
6.8M
↓ 51.18%
Net Income
-31.4M
↑ 14.53%
Net Profit Margin
-465.32%
↓ 266.97%
Q4 FY22Q/Q Change
Revenue
2.9M
↓ 57.74%
Net Income
-36.1M
↑ 14.79%
Net Profit Margin
-1.3K%
↓ 798.77%
Q1 FY23Q/Q Change
Revenue
3.8M
↑ 31.71%
Net Income
-33.9M
↓ 5.93%
Net Profit Margin
-902.85%
↑ 361.24%
Q2 FY23Q/Q Change
Revenue
2.7M
↓ 29.13%
Net Income
-35.9M
↑ 5.85%
Net Profit Margin
-1.3K%
↓ 445.57%
Q3 FY23Q/Q Change
Revenue
11.1M
↑ 315.62%
Net Income
-27.0M
↓ 24.73%
Net Profit Margin
-244.19%
↑ 1104.23%
Q4 FY23Q/Q Change
Revenue
3.3M
↓ 70.55%
Net Income
-34.8M
↑ 28.54%
Net Profit Margin
-1.1K%
↓ 821.56%
FY18Y/Y Change
Total Assets
146.5M
-
Total Liabilities
226.2M
-
FY19Y/Y Change
Total Assets
118.3M
↓ 19.27%
Total Liabilities
230.2M
↑ 1.76%
FY20Y/Y Change
Total Assets
400.1M
↑ 238.35%
Total Liabilities
119.3M
↓ 48.16%
FY21Y/Y Change
Total Assets
506.8M
↑ 26.65%
Total Liabilities
117.2M
↓ 1.83%
FY22Y/Y Change
Total Assets
430.8M
↓ 14.98%
Total Liabilities
141.6M
↑ 20.87%
FY23Y/Y Change
Total Assets
376.5M
↓ 12.62%
Total Liabilities
130.3M
↓ 7.96%
Q3 FY22Q/Q Change
Total Assets
461.4M
↓ 6.3%
Total Liabilities
143.3M
↓ 3.13%
Q4 FY22Q/Q Change
Total Assets
430.8M
↓ 6.63%
Total Liabilities
141.6M
↓ 1.15%
Q1 FY23Q/Q Change
Total Assets
396.0M
↓ 8.08%
Total Liabilities
133.6M
↓ 5.68%
Q2 FY23Q/Q Change
Total Assets
375.0M
↓ 5.31%
Total Liabilities
141.3M
↑ 5.79%
Q3 FY23Q/Q Change
Total Assets
333.0M
↓ 11.2%
Total Liabilities
117.0M
↓ 17.21%
Q4 FY23Q/Q Change
Total Assets
376.5M
↑ 13.04%
Total Liabilities
130.3M
↑ 11.41%
FY18Y/Y Change
Operating Cash Flow
-17.0M
-
Investing Cash Flow
36.9M
-
Financing Cash Flow
2.0M
-
FY19Y/Y Change
Operating Cash Flow
55.6M
↓ 427.51%
Investing Cash Flow
-1.6M
↓ 104.39%
Financing Cash Flow
244.0K
↓ 87.56%
FY20Y/Y Change
Operating Cash Flow
-67.2M
↓ 220.92%
Investing Cash Flow
-190.5M
↑ 11659.57%
Financing Cash Flow
348.9M
↑ 142904.92%
FY21Y/Y Change
Operating Cash Flow
-87.0M
↑ 29.32%
Investing Cash Flow
-189.3M
↓ 0.61%
Financing Cash Flow
171.4M
↓ 50.88%
FY22Y/Y Change
Operating Cash Flow
-105.9M
↑ 21.82%
Investing Cash Flow
58.4M
↓ 130.86%
Financing Cash Flow
1.1M
↓ 99.33%
Q3 FY22Q/Q Change
Operating Cash Flow
-28.0M
↑ 26.24%
Investing Cash Flow
19.9M
↓ 40.07%
Financing Cash Flow
361.0K
↑ 39.38%
Q4 FY22Q/Q Change
Operating Cash Flow
-29.1M
↑ 3.95%
Investing Cash Flow
9.3M
↓ 53.38%
Financing Cash Flow
47.0K
↓ 86.98%
Q1 FY23Q/Q Change
Operating Cash Flow
-33.1M
↑ 13.72%
Investing Cash Flow
15.1M
↑ 63.16%
Financing Cash Flow
-684.0K
↓ 1555.32%
Q2 FY23Q/Q Change
Operating Cash Flow
-19.0M
↓ 42.65%
Investing Cash Flow
15.1M
↑ 0.0%
Financing Cash Flow
-746.0K
↑ 9.06%

Technicals Summary

Sell

Neutral

Buy

C4 Therapeutics, Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
C4 Therapeutics, Inc
C4 Therapeutics, Inc
-16.12%
265.43%
116.04%
-78.25%
-73.05%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
C4 Therapeutics, Inc
C4 Therapeutics, Inc
NA
NA
NA
-1.85
-0.49
-0.22
NA
4.07
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
C4 Therapeutics, Inc
C4 Therapeutics, Inc
Buy
$471.3M
-73.05%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • Wasatch Advisors Inc.

    10.41%

  • RA Capital Management, LLC

    7.11%

  • COMMODORE CAPITAL LP

    5.54%

  • T. Rowe Price Associates, Inc.

    3.73%

  • ArrowMark Colorado Holdings, LLC (ArrowMark Partners)

    3.12%

  • Vanguard Group Inc

    2.91%

Corporate Announcements

  • C4 Therapeutics, Inc Earnings

    C4 Therapeutics, Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

c4 therapeutics is an early stage drug discovery company whose mission is to harness targeted protein degradation to develop therapeutics for a broad range of diseases. the centerpiece of our approach is the degronimid® platform, which enables highly selective small molecule binders to target disease causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system.

Organization
C4 Therapeutics, Inc
Employees
145
CEO
Mr. Andrew J. Hirsch M.B.A.
Industry
Health Technology

Discover More

FAQs